Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Not Likely To Hold Its Peace At Merck/Schering Altar

Executive Summary

Merck and Schering-Plough are talking up the future - the commercial, pipeline and cost savings advantages of a proposed $41.1 billion merger - like newlyweds who have already tied the knot, danced the first dance and cut the cake. But there's an uninvited guest at the affair, Johnson & Johnson, a third-party with bargaining power that could step in to thwart Merck and Schering's happily ever after

You may also be interested in...



Merck And J&J Settle Remicade Dispute By Redrawing The Map

Johnson & Johnson Inc. and Merck & Co. Inc. settled their two-year dispute over Remicade (infliximab) and its successor Simponi (golimumab) April 15, avoiding an arbitrator's decision by striking a revised agreement under which each will retain some territorial rights to the drugs

Merck And J&J Settle Remicade Dispute By Redrawing The Map

Rather than let an arbitration panel decide the fate of two anti-TNF drugs, Merck surrenders many territories but holds onto Europe.

J&J vs. Merck: What Might A Remicade Settlement Look Like?

Analysts say Merck has a good chance of prevailing in arbitration over J&J's agreement with Schering to co-distribute Remicade but that the two parties may opt to settle.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel